Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676 is registered in ClinicalTrials.gov with Crossbow Therapeutics, Inc. as lead sponsor.

NCT NCT06994676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06994676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Lead sponsor
Crossbow Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 16, 2025
Completion date
June 30, 2027
Enrollment
72 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

aml - acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia (cmml), high-risk myelodysplastic syndrome